Pyxis Oncology Inc (NASDAQ: PYXS) shares rose 5.91% to $4.12 in overnight trading following a leadership announcement and a scheduled presentation of clinical data.
The Boston-based clinical-stage biopharmaceutical company appointed Thomas Civik as its permanent Chief Executive Officer and Chairman, effective September 4. Civik, who had served as interim CEO since February, previously led Five Prime Therapeutics through its $1.9 billion acquisition by Amgen Inc (NASDAQ: AMGN). He has also served as chairman for ImCheck Therapeutics and Repare Therapeutics during their respective acquisitions.
Founder John Flavin has transitioned to the role of Lead Independent Director, continuing to serve on the board after leading the company since its founding.
Pyxis Oncology announced it will host a live webcast on Wednesday at 7:30 a.m. Eastern to present updated Phase 1 data on micvotabart pelidotin (MICVO), the company's lead antibody-drug conjugate. The trial is evaluating MICVO as a monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who have received prior treatment, classified as second-line and beyond (2L+).
Dr. Alan L. Ho of Memorial Sloan Kettering Cancer Center will join company management to discuss safety, efficacy, and next steps.
According to the report, Pyxis Oncology has a market capitalization of approximately $324.46 million. The stock has traded between a 52-week high of $5.55 and a 52-week low of $1.03. Over the past 12 months, the small-cap biotech stock has gained 98.47%.
